bonitapokerroom| Yunnan Baiyao: The first subject enrolled in the Chinese Phase I/IIa clinical trial of Chuangxin Nuclear Drug INR101 Injection completed

Securities Times e Company NewsbonitapokerroomOn May 24, Yunhe Pharmaceutical (Tianjin) Co., Ltd.(referred to as "Yunhe Pharmaceutical"), a wholly-owned subsidiary of Yunnan Baiyao (000538), conducted the Phase I/IIa clinical trial of the innovative nuclear drug INR101 injection at Beijing Friendship Hospital Affiliated to Capital Medical University completed the enrollment and administration of the first healthy subject. INR101 injection is an innovative chemical Class 1 radiologic diagnostic drug developed by Yunhe Pharmaceutical. It is suitable for PET imaging of PSMA positive lesions in prostate cancer patients.

Tags:

Prev: europeanbaccarat| Guan Yuxiang: As a corporate leader, you cannot rely on others, you can only rely on yourself
Next: nlholdem| Foreign media: Scholz said he could not provide "Taurus" missiles to Ukraine because he had the responsibility to prevent "escalation of war."